Phase I/II Combination With Irinotecan- Erbitux
Part 1: To define the recommended dose of brivanib that can be safely administered in combination with Erbitux (Cetuximab) and irinotecan to subjects with advanced metastatic colorectal cancer (MCRC)

Part 2: To compare median duration of progression free survival (PFS)
Metastatic Colorectal Cancer (MCRC)
DRUG: Cetuximab|DRUG: Irinotecan|DRUG: Brivanib|DRUG: Brivanib|DRUG: Brivanib Placebo
Pharmacokinetics and markers of exploratory coagulation pathways will be conducted during this trial, PK C1D1-C2-D3, biomarker throughout the study|Safety and tolerability of interventions will be collected, throughout the study on Part II
Efficacy on tumor progression and progression free survival will be collected on all enrolled subjects, throughout the study on Part II
Part 1: To define the recommended dose of brivanib that can be safely administered in combination with Erbitux (Cetuximab) and irinotecan to subjects with advanced metastatic colorectal cancer (MCRC)

Part 2: To compare median duration of progression free survival (PFS)